AUS
NZ
UK
CA
USA
IND
On July 20, 2026, Kevin R. Sayer, Executive Chair of Dexcom Inc., sold 26,756 shares of the company's stock, as disclosed in a Securities and Exchange Commission filing. The shares were sold at a weighted average price of $76.3193 each under a Rule 10b5-1 trading plan established in February 2026. Post-sale, Sayer retains direct beneficial ownership of 328,970 shares, which includes over 106,000 unvested restricted stock units scheduled to vest through March 2028.
Key Points
- NASDAQ: DXCM
- Kevin R. Sayer sold 26,756 shares on July 20, 2026, at a weighted average price of $76.3193
- Transaction executed under a Rule 10b5-1 trading plan adopted on February 18, 2026, facilitating orderly share disposition
- Sayer retains 328,970 shares, including 106,972 unvested restricted stock units vesting through March 2028
Details of Executive Share Sale
Kevin R. Sayer, serving as Executive Chair and director of Dexcom Inc., completed a sale of 26,756 shares of Dexcom common stock on July 20, 2026. The transaction was carried out through multiple trades rather than a single block, with individual trade prices ranging from $75.80 to $76.62 per share during the execution period.
The overall weighted average price for the shares sold that day was $76.3193 per share. After this sale, Sayer's direct beneficial ownership stands at 328,970 shares, encompassing both fully vested shares and a significant number of unvested restricted stock units that form part of his long-term executive compensation.
Rule 10b5-1 Trading Plan Adoption and Purpose
This share sale was conducted pursuant to a Rule 10b5-1 trading plan that Sayer adopted on February 18, 2026. Such prearranged plans enable insiders to systematically sell shares according to predetermined terms, providing an affirmative defense under securities laws against insider trading allegations. By implementing this plan, Sayer established a structured framework for the orderly sale of his shares, independent of market timing decisions.
The Rule 10b5-1 plan offers a compliant method for executives to manage their equity holdings while adhering to insider trading regulations. The plan adopted in February 2026 governed the July 20 transaction and may authorize further sales under its terms, exemplifying transparency in executive equity management at Dexcom.
Restricted Stock Units and Vesting Timeline
Within the 328,970 shares retained by Sayer, 106,972 are unvested restricted stock units granted at different times with staggered vesting schedules. These units represent a key component of Dexcom’s equity-based compensation strategy, aligning executive incentives with shareholder value over time.
The restricted stock units are divided into three grant cohorts: 32,749 units granted on March 8, 2026, vesting through March 8, 2027; 56,993 units granted on March 8, 2025, vesting through March 8, 2028; and 17,230 units granted on March 8, 2024, vesting through March 8, 2027. This multi-year vesting approach supports sustained executive retention and performance alignment.
Overview of Dexcom’s Business and Market Position
Dexcom Inc. is a medical technology company specializing in continuous glucose monitoring (CGM) systems for diabetes management worldwide. The company designs and markets wearable glucose monitors and related software that provide real-time glucose data and alerts. Operating within the growing diabetes care and digital health sectors, Dexcom benefits from rising diabetes prevalence and increasing demand for remote monitoring solutions.
Dexcom’s revenue is driven by sales of CGM hardware devices and recurring sensor replacements and subscription services. Its customer base includes healthcare providers, payers, and patients, with international markets offering significant expansion potential. The company competes in a dynamic environment shaped by regulatory approvals, reimbursement policies, and technological innovation.
Insider Ownership and Executive Compensation Structure
Following the July 2026 transaction, Sayer holds 328,970 shares, reflecting his substantial equity stake as Executive Chair and board member. His ownership includes both vested shares and restricted stock units, consistent with executive compensation practices combining cash and long-term equity incentives to promote retention and performance.
The vesting schedule of Sayer’s restricted units indicates ongoing equity awards that will vest over the next several years, contingent on continued service. This multi-cohort vesting pattern suggests periodic equity grants aligned with annual compensation reviews or corporate initiatives.
Transaction Execution Details and Price Range
The sale on July 20, 2026, was executed via multiple trades with prices between $75.80 and $76.62 per share. The weighted average price of $76.3193 represents the aggregate price across all shares sold that day. Executing the sale in tranches is a common practice for sizable transactions to minimize market impact and optimize pricing.
Sayer has committed to providing detailed information on the number of shares sold at each price point upon request by the SEC, the company, or shareholders. This transparency ensures regulatory compliance and investor confidence regarding the transaction’s execution.
Compliance with Insider Trading Regulations
The transaction was reported in an insider trading disclosure filed on July 21, 2026, fulfilling Section 16 reporting obligations that require disclosure within two trading days of share transactions by officers and directors. The filing confirmed the sale was conducted under a Rule 10b5-1 trading plan, establishing a lawful framework for the share disposition.
This regulatory framework promotes transparency about changes in insider ownership while protecting insiders from liability when trades are executed under prearranged plans during non-trading windows. Sayer’s adherence to these protocols underscores his compliance with securities regulations and commitment to transparent governance.
Executive Leadership and Governance Roles
Kevin R. Sayer serves as both Executive Chair and a director of Dexcom, positioning him among the company’s top leadership responsible for strategic oversight and corporate governance. His substantial equity holdings, including the 328,970 shares retained after the July sale, demonstrate significant personal investment in Dexcom’s success and shareholder value creation.
The combination of executive and board roles reflects a governance model where senior management maintains alignment with shareholders through meaningful equity ownership. The extended vesting schedule of Sayer’s restricted stock units through 2028 suggests his anticipated continued leadership role over the next several years.
Industry Trends in Executive Equity Compensation
Within the medical device and digital health sectors, equity-based compensation—especially restricted stock units with multi-year vesting—is a prevalent strategy to attract and retain executive talent while aligning incentives with shareholder returns. Dexcom’s use of March vesting dates and staggered vesting periods aligns with these industry standards.
Sayer’s July 2026 share sale is part of ongoing equity portfolio management conducted under a prearranged trading plan. Such insider sales are common in publicly traded medical technology companies and typically reflect personal liquidity or diversification rather than company outlook. The retention of a significant shareholding post-sale indicates confidence in Dexcom’s long-term growth prospects.
